Recommendations are not in order of importance. The NCR may form the of future NCSP-R cervical cancer audits and reviews. The NCR inform the NCSP-R of any cervical cancer diagnosis. The NCR use the date of histological diagnosis of cancer. The NCSP-R enable data management to support future cervical cancer audits and reviews. For future reviews consideration should be given to recording at the time of diagnosis (i.e. in time”) identification, verification, and “real classification of the diagnosis and staging of cervical cancer cases for the NCSP-R and NCR. For future audits and reviews, a case control methodology from a population based registry should be used to estimate the protective effect of cervical screening. A consistent definition of regular screening that can be applied to both monitoring of the screened population and to the of women with cancer should be agreed upon. Emphasis should continue to be placed on both enrolling and maintaining participation in the screening programme. To prioritise improved access and quality of screening, and treatment of cervical cancer for Māori women and the more socially deprived. Intervention strategies should take into consideration both the practical and cultural needs of these groups. Improve collection and recording of ethnicity data on the NCSP-R, including the recording of more than one ethnic time” data collection may enable improved collection of ethnicity “Real data. The protective effects of screening in relation to age continue to be monitored. That should be taken to ensure the regular participation in screening from the recommended age of commencement. For the purpose of cervical cancer review that micro-invasive tumours continue to be distinguished from other cancers. The NCSP should continue to aim to reduce the incidence of all cervical cancers, including tumours. Formal review of normal screening tests in women who develop cervical cancer should be undertaken and reported on for educational and quality improvement purposes. We endorse the introduction of HPV based screening, efforts should be made to ensure that there is no reduction in 5 year cervical screening coverage rates. A formal clinical case review for patients who have developed cervical cancer following previous screen detected abnormalities should be performed. This should be used to inform the programme, laboratories and medical practitioners of any modifiable factors that have contributed to the outcome.
Recommendations are not in order of importance. The NCR may form the of future NCSP-R cervical cancer audits and reviews. The NCR inform the NCSP-R of any cervical cancer diagnosis. The NCR use the date of histological diagnosis of cancer. The NCSP-R enable data management to support future cervical cancer audits and reviews. For future reviews consideration should be given to recording at the time of diagnosis (i.e. in “real time”) identification, verification, and classification of the diagnosis and staging of cervical cancer cases for the NCSP-R and NCR. For future audits and reviews, a case control methodology from a population based registry should be used to estimate the protective effect of cervical screening. A consistent definition of regular screening that can be applied to both monitoring of the screened population and to the of women with cancer should be agreed upon. Emphasis should continue to be placed on both enrolling and maintaining participation in the screening programme. To prioritise improved access and quality of screening, and treatment of cervical cancer for Māori women and the more socially deprived. Intervention strategies should take into consideration both the practical and cultural needs of these groups. Improve collection and recording of ethnicity data on the NCSP-R, including the recording of more than one ethnic “Real time” data collection may enable improved collection of ethnicity data. The protective effects of screening in relation to age continue to be monitored. That should be taken to ensure the regular participation in screening from the recommended age of commencement. For the purpose of cervical cancer review that micro-invasive tumours continue to be distinguished from other cancers. The NCSP should continue to aim to reduce the incidence of all cervical cancers, including tumours. Formal review of normal screening tests in women who develop cervical cancer should be undertaken and reported on for educational and quality improvement purposes. We endorse the introduction of HPV based screening, efforts should be made to ensure that there is no reduction in 5 year cervical screening coverage rates. A formal clinical case review for patients who have developed cervical cancer following previous screen detected abnormalities should be performed. This should be used to inform the programme, laboratories and medical practitioners of any modifiable factors that have contributed to the outcome.